Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
